207 related articles for article (PubMed ID: 9918130)
21. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
22. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
Woolhouse NM
Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
[No Abstract] [Full Text] [Related]
23. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
[TBL] [Abstract][Full Text] [Related]
24. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Lennard MS
Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
[TBL] [Abstract][Full Text] [Related]
26. Association of tau gene polymorphism with Parkinson's disease.
Zappia M; Annesi G; Nicoletti G; Serra P; Arabia G; Pugliese P; Messina D; Caracciolo M; Romeo N; Annesi F; Pasqua AA; Spadafora P; Civitelli D; Romeo N; Epifanio A; Morgante L; Quattrone A
Neurol Sci; 2003 Oct; 24(3):223-4. PubMed ID: 14600827
[TBL] [Abstract][Full Text] [Related]
27. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis of Parkinson's disease and exposure to pesticides.
Priyadarshi A; Khuder SA; Schaub EA; Shrivastava S
Neurotoxicology; 2000 Aug; 21(4):435-40. PubMed ID: 11022853
[TBL] [Abstract][Full Text] [Related]
30. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population.
Satake W; Mizuta I; Suzuki S; Nakabayashi Y; Ito C; Watanabe M; Takeda A; Hasegawa K; Sakoda S; Yamamoto M; Hattori N; Murata M; Toda T
Neuroreport; 2007 Jun; 18(9):937-40. PubMed ID: 17515805
[TBL] [Abstract][Full Text] [Related]
32. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 genotype and the incidence of anal and vulvar cancer.
Chen C; Cook LS; Li XY; Hallagan S; Madeleine MM; Daling JR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):317-21. PubMed ID: 10207635
[TBL] [Abstract][Full Text] [Related]
34. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
35. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
36. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.
Mellick GD; Maraganore DM; Silburn PA
Neurosci Lett; 2005 Feb; 375(2):112-6. PubMed ID: 15670652
[TBL] [Abstract][Full Text] [Related]
37. A genetic study of Parkinson's disease.
De Michele G; Filla A; Marconi R; Volpe G; D'Alessio A; Scala R; Ambrosio G; Campanella G
J Neural Transm Suppl; 1995; 45():21-5. PubMed ID: 8748605
[TBL] [Abstract][Full Text] [Related]
38. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset.
Hadjigeorgiou GM; Xiromerisiou G; Gourbali V; Aggelakis K; Scarmeas N; Papadimitriou A; Singleton A
Mov Disord; 2006 Apr; 21(4):534-9. PubMed ID: 16250025
[TBL] [Abstract][Full Text] [Related]
39. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
[TBL] [Abstract][Full Text] [Related]
40. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
